Antitrust Division 2021 – Federal Register Recent Federal Regulation Documents

Notice is hereby given pursuant to section 708 of the Defense Production Act of 1950 (``DPA'') for the Plan of Action to Establish a National Strategy for the Manufacture, Allocation, and Distribution of Medical Devices to Respond to COVID-19 (``Medical Devices Plan of Action''), the Plan of Action to Establish a National Strategy for the Manufacture, Allocation, and Distribution of Medical Gases to Respond to COVID-19 (``Medical Gases Plan of Action''), the Plan of Action to Establish a National Strategy for the Manufacture, Allocation and Distribution of Diagnostic Test Kits and other Testing Components to Respond to COVID-19 (``Diagnostic Test Kits Plan of Action''), and the Plan of Action to Establish a National Strategy for the Manufacture, Allocation, and Distribution of Drug Products, Drug Substances, and Associated Medical Devices to Respond to COVID-19 (``Drug Products Plan of Action'') proposed by the Federal Emergency Management Agency (``FEMA''), that the Acting Assistant Attorney General finds for each that the purposes of section 708(c)(1) of the DPA may not reasonably be achieved through a plan of action having less anticompetitive effects or without any plan of action. Given these findings, the Medical Devices Plan of Action, the Medical Gases Plan of Action, the Diagnostic Test Kits Plan of Action, and the Drug Products Plan of Action may become effective following the publication of this notice. Given these findings, the Medical Devices Plan of Action, the Medical Gases Plan of Action, the Diagnostic Test Kits Plan of Action, and the Drug Products Plan of Action may become effective following the publication of this notice.